Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
A-Share Information
H-Share Information
2024.07.12
POSITIVE PROFIT ALERT ANNOUNCEMENT FOR THE ESTIMATED 2024 INTERIM RESULTS
2024.07.12
ag真人平台官方：2024年半年度业绩预告
2024.04.30
ag真人平台官方：关于续聘会计师事务所的公告
2024.04.30
ag真人平台官方：关于2023年年度股东大会增加临时提案暨股东大会补充通知的公告
2024.04.30
ag真人平台官方：董事会决议公告
2024.04.30
ag真人平台官方：关于举行2023年年度业绩说明会的公告
2024.04.30
ag真人平台官方：2024年一季度报告
2024.04.30
2023 Annual Report
2024.04.30
2023 ESG Report
2024.04.30
2023 AGM Circular
第一页
上一页
1
2
3
4
5
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
